Results 71 to 80 of about 7,521 (213)

Advances in immunomodulating therapy of HBV infection [PDF]

, 2000
Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers ...
Hui, CK, Lau, GKK
core  

Long-Term Lamivudine Treatment of Children with Chronic Hepatitis B: Durability of Therapeutic Responses and Safety [PDF]

, 2008
Lamivudine has been demonstrated safe and efficacious in the short term in a large cohort of children with chronic hepatitis B (CHB), but optimal duration of treatment has not been elucidated and limited data on the safety of long-term lamivudine ...
Gardner, SD, Jonas, MM, Little, NR, Pó, I   +3 more
core   +1 more source

A Systematic Review and Model‐Based Meta‐Analysis of Pegylated‐Interferon‐α‐Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Pegylated‐interferon‐α (Peg‐IFNα) is a treatment option for chronic hepatitis B virus (HBV) infection. To quantify treatment response variability, we conducted a model‐based meta‐analysis (MBMA) of hepatitis B surface antigen (HBsAg) loss, defined as a binary outcome based on HBsAg levels falling below the limit of detection, with Peg‐IFNα ...
Nathan J. Hanan, Matthew L. Zierhut, Ahmed Nader, Anadi Mahajan, Amandeep Kaur, Krishna Kumar, Susan A. Dixon, Joyeta Das, Mindy Magee, Dickens Theodore, Vera Gielen   +10 more
wiley   +1 more source

Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy [PDF]

, 2013
BACKGROUND: Improving the HBe seroconversion rate of patients without HBeAg loss after long-term lamivudine therapy has become an urgent clinical problem that we have to face. Unfortunately, there is no consensus on the mananement of these patients.
Hui-Yan Zhang, Jian-Ping You, Qing Mao, Xu-Qing Zhang   +3 more
core   +1 more source

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 1, Page 132-144, January 2026.
In East Asian patients with chronic hepatitis B, rates of virologic suppression through 5 years were high in those treated continuously with tenofovir alafenamide (TAF) and in those switched from tenofovir disoproxil fumarate (TDF) to TAF. Improved renal and bone safety was observed in patients switching from TDF to TAF.
Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti   +15 more
wiley   +1 more source

Mutations in pre-core and basal-core promoter regions of hepatitis B virus in chronic HBV patients from Golestan, Iran [PDF]

, 2014
Objective(s): It has been reported that the mutation of the pre-core (PC) and basal-core promoter (BCP) may play an important role in the development of HBV-related hepatocellular carcinoma (HCC).
Bazouri, M., Ghaemi, A., Javid, N., Moradi, A., Tabarraei, A., Zhand, S.   +5 more
core   +2 more sources

New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation [PDF]

, 2016
open5noThe hepatitis B virus (HBV) infects more than 260 million people globally, with increasing incidence, especially in developing countries.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Russo, Francesco Paolo, Zanetto, Alberto   +4 more
core   +1 more source

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 231-241, January 2026.
We evaluated long‐term outcomes following nucleos(t)ide analogue discontinuation in HBeAg‐negative chronic hepatitis B. HBsAg loss was infrequent. Early HBsAg loss occurred in patients with low end‐of‐treatment HBsAg levels and without ALT flare, whilst late HBsAg loss typically followed ALT flares and was associated with higher end‐of‐treatment HBsAg ...
Simon J. Hume, Samuel Hall, Gareth Burns, Sara Vogrin, Daniel Tassone, Paul Desmond, Dilip Ratnam, Miriam T. Levy, Rohit Sawhney, Amanda Nicoll, Zina Valaydon, Simone I. Strasser, Meng Ngu, Marie Sinclair, Chris Meredith, Gayle V. Matthews, Kumar Visvanathan, Jacinta A. Holmes, Alexander J. Thompson   +18 more
wiley   +1 more source

Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients [PDF]

, 2007
AIM: To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients. METHODS: Seventy-one patients received treatment with lamivudine, interferon alpha (IFN-alpha 2b) or sequential therapy with ...
Chen, Xin-Yue, Chen, Yong, Han, Zhong-Hou, Hou, Dong-Ming, Ivan, Hadad, Li, Jun, Lu, Hai-Ying, Si, Chong-Wen, Yu, Yan-Yan, Zeng, Zheng, Zhuang, Li-Wei   +10 more
core   +1 more source

Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood — Clinical, Virological and Immunological Long‐Term Follow‐Up

Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Oncology patients receiving cytostatic therapy used to be at high risk of HBV infection when HBV screening measures were less reliable. Infections acquired under these conditions often persist, like those acquired perinatally or during early infancy.
Thomas Baumgarten, Felix Lehmann, Tina Senff, Heiko Slanina, Christian G. Schüttler, Andreas Walker, Wolfram H. Gerlich, Reinald Repp, Jörg Timm, Dieter Glebe, Markus Metzler   +10 more
wiley   +1 more source